Angelini Ventures Participates in Therini Bio’s Funding
In a significant move for the biotech industry, Angelini Ventures proudly announces its investment in a $39 million extension of the Series A financing round for Therini Bio. This U.S.-based clinical biotech company specializes in developing innovative fibrin-targeting immunotherapies aimed at treating neurodegenerative diseases characterized by vascular dysfunction.
Investment Highlights and Collaborating Partners
Angelini Ventures joins a notable consortium of international healthcare investors that includes Apollo Health Ventures, SV Health Investors’ Biotech Fund, the Dementia Discovery Fund, and Eli Lilly among others. This infusion of funds brings Therini Bio's total financing from the Series A round to an impressive $75 million, indicating strong confidence in the company's mission and potential impact.
Focus on Advancing Clinical Research
The investment provides critical support for Therini Bio's Phase 1b studies, aiming to evaluate its promising candidate, THN391. Designed as a first-in-class monoclonal antibody, THN391 holds potential in selectively averting fibrin-mediated neuroinflammation, addressing pressing conditions such as Alzheimer’s Disease and Diabetic Macular Edema.
The Vision Behind the Investment
Dr. Thomas Thestrup, Senior Principal at Angelini Ventures, expressed enthusiasm about supporting Therini Bio's pioneering approach. He remarked, “We are eager to enhance the fight against neurodegenerative diseases by targeting their underlying inflammatory drivers. Therini Bio's development of a selective antibody therapy targeting fibrin-mediated inflammation shows great promise for Alzheimer’s and other CNS disorders.”
New Board Presence and Strategic Oversight
As part of this partnership, Fabrizio Calisti, M.D., Medical Director at Angelini Ventures, will take on the role of Board Observer at Therini Bio. This strategic involvement indicates Angelini Ventures' commitment to ensuring effective governance and guidance as Therini progresses through its clinical phases.
Advancing Towards Innovative Therapeutics
Dr. Tara Nickerson, the Chief Executive Officer of Therini Bio, articulated gratitude for the backing of such a prestigious investment group. She noted that their collaboration would help propel the advancement of THN391 through clinical trials, bringing hope for effective treatments against debilitating conditions like Alzheimer’s and Diabetic Macular Edema.
About Angelini Ventures
Angelini Ventures serves as the venture capital branch of Angelini Industries, focused on investing in transformative innovations in the BioTech and Digital Health fields. The firm plans to invest €300 million globally, leveraging a diverse team of advisors and partners to accelerate growth in biotech companies.
About Angelini Industries
Founded in 1919, Angelini Industries has evolved into a multinational group that employs around 5,800 individuals across 21 different countries, generating over two billion euros in revenue. Their strategic investments and a strong emphasis on research and development make them a key player within the sectors they operate in.
About Therini Bio
Therini Bio is a forward-thinking clinical-stage biotech company dedicated to developing immunotherapies that target neuroinflammation caused by vascular dysfunction. The company's innovative therapies are aimed at conditions such as Alzheimer’s disease and Diabetic Macular Edema, where reducing neuroinflammation is crucial to improving patient outcomes. Their extensive network of investors reflects confidence in their vision to transform treatment options.
Frequently Asked Questions
What is the purpose of Angelini Ventures' investment in Therini Bio?
The investment aims to support Therini Bio's clinical trials evaluating their innovative therapies for neurodegenerative diseases.
What specific therapies is Therini Bio developing?
Therini Bio is developing immunotherapies that target fibrin-mediated neuroinflammation, particularly for Alzheimer's disease and Diabetic Macular Edema.
Who are the notable investors alongside Angelini Ventures?
Investors alongside Angelini Ventures include Apollo Health Ventures, SV Health Investors, Eli Lilly, among others.
What role does Fabrizio Calisti have in Therini Bio?
Fabrizio Calisti will serve as a Board Observer for Therini Bio, ensuring strategic oversight of their clinical efforts.
What is the long-term vision of Angelini Ventures?
Angelini Ventures aims to invest in disruptive innovations in healthcare sectors, supporting growth in transformative biotech companies globally.
